Xi Liu
Gründer bei BEIJING STRONG BIOTECHNOLOGIES,INC.
Vermögen: 171 Mio $ am 30.04.2024
Aktive Positionen von Xi Liu
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| BEIJING STRONG BIOTECHNOLOGIES,INC. | Direktor/Vorstandsmitglied | 29.03.2001 | - |
| Vorstandsvorsitzender | 16.03.2011 | - | |
| Gründer | 29.03.2001 | - | |
Fuzhou Maixin Biotech Co., Ltd.
 Fuzhou Maixin Biotech Co., Ltd. Medical/Nursing ServicesHealth Services Part of Beijing Strong Biotechnologies, Inc., Fuzhou Maixin Biotech Co., Ltd. engages in the production, research & development, and sales of tissue-based diagnostics, specifically IHC antibodies, reagents, and the automation of IHC and ISH. The private company is based in Fuzhou, China. Fuzhou Maixin Biotech Co. was acquired by Fuzhou Maixin Biotech Co. Ltd. /Private Group/ on September 30, 2020 for $255.21 million. The Chinese company was founded in 1993. The CEO is Xiao Ya Wang. | Direktor/Vorstandsmitglied | 30.09.2020 | - |
Karriereverlauf von Xi Liu
Ausbildung von Xi Liu
| Harbin Engineering University | Graduate Degree |
| Institute of Automation Chinese Academy of Sciences | Doctorate Degree |
Statistik
International
| China | 5 |
Operativ
| Director/Board Member | 2 |
| Chief Executive Officer | 1 |
| Founder | 1 |
Sektoral
| Consumer Services | 3 |
| Health Technology | 2 |
| Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BEIJING STRONG BIOTECHNOLOGIES,INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Fuzhou Maixin Biotech Co., Ltd.
Fuzhou Maixin Biotech Co., Ltd. Medical/Nursing ServicesHealth Services Part of Beijing Strong Biotechnologies, Inc., Fuzhou Maixin Biotech Co., Ltd. engages in the production, research & development, and sales of tissue-based diagnostics, specifically IHC antibodies, reagents, and the automation of IHC and ISH. The private company is based in Fuzhou, China. Fuzhou Maixin Biotech Co. was acquired by Fuzhou Maixin Biotech Co. Ltd. /Private Group/ on September 30, 2020 for $255.21 million. The Chinese company was founded in 1993. The CEO is Xiao Ya Wang. | Health Services |
